This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 5.56% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $807.79, indicating a +0.39% shift from the previous trading day.
Zacks Market Edge Highlights: LLY and NVO
by Zacks Equity Research
LLY and NVO have been highlighted in this Market Edge article.
Is Eli Lilly's Stock in a Bubble?
by Tracey Ryniec
Shares of Eli Lilly are up 150% over the last 2 years as investors are bullish about the new weight loss drugs. Is it too hot to handle?
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline
by Zacks Equity Research
Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.
What Lies in Store for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Time for Healthcare ETFs?
by Sanghamitra Saha
Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $865.97, indicating a +0.99% shift from the previous trading day.
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
by Sanghamitra Saha
Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
by Sundeep Ganoria
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports second-quarter results.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The 5 Most Important Stocks to Watch During Q2 Earnings Season
by Tracey Ryniec
All eyes will be on these 5 companies over the next few weeks. Will another beat add fuel to this already red-hot stock market?
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
by Sundeep Ganoria
Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
by Zacks Equity Research
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
by Zacks Equity Research
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $941.60, signifying a -0.93% move from its prior day's close.
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
The Zacks Analyst Blog Eli Lilly, UnitedHealth and Tile Shop
by Zacks Equity Research
Eli Lilly, UnitedHealth and Tile Shop are included in this Analyst Blog.